^
    Back
    Association details:
    Biomarker:DNMT3A mutation
    Cancer:Acute Myelogenous Leukemia
    Regimen: (aclarubicin + cytarabine + decitabine + granulocyte-colony stimulating factor (GCSF))
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    ASH 2021
    Title:

    The Prognosis of Intermediate- and High-Risk Young AML Patients Who Did Not Receive Allo-HSCT Treated with Intensive Chemotherapy Is Not Superior to That of Elderly AML Patients Treated with the D-CAG Regimen

    Published date:
    11/04/2021
    Excerpt:
    Patients harboring FLT3-ITD, DNMT3A, IDH2, TP53 and DNA methylation associated mutations were found to benefit more from the D-CAG regimen in comparison to intensive chemotherapy.
    DOI:
    10.1182/blood-2021-149060